Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

This publication has 12 references indexed in Scilit:

• Apples and oranges: building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials.
  Journal of Clinical Oncology, 1998
• Androgen Antagonistic Effect of Estramustine Phosphate (EMP) Metabolites on Wild-Type and Mutated Androgen Receptor
  Biochemical Pharmacology, 1998
• Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines
  Published by Wiley ,1997
• Symptomatic Improvement Associated With Combined Estramustine and Vinblastine Chemotherapy for Metastatic Prostate Cancer
  American Journal of Clinical Oncology, 1996
• Acid phosphatase: defining a role in androgen-independent prostate cancer
  Urology, 1996
• Docetaxel.
  Journal of Clinical Oncology, 1995
• Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
  Journal of Clinical Oncology, 1992
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
  Investigational New Drugs, 1992
• Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype
  British Journal of Cancer, 1991
• Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
  JNCI Journal of the National Cancer Institute, 1991